{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-003550","form_type":"8-K","ticker":"CNSP","cik":"0001729427","company_name":"CNS Pharmaceuticals, Inc.","filed_at":"2024-05-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.777464+00:00","generated_at":"2026-06-01T21:31:25.245013+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CNS Pharma Q1 net loss $3.5M; Berubicin GBM trial topline data H1 2025","bullets":["Net loss $3.5M for Q1 2024, vs $4.9M in Q1 2023; R&D expense down to $2.4M from $3.6M.","Cash at March 31, 2024 was ~$0.8M; no revenue reported.","Enrollment completed in potentially pivotal Berubicin trial for GBM; DSMB recommended continuation in Dec 2023.","Topline data from Berubicin study expected first half 2025.","FDA granted Fast Track and Orphan Drug designations for Berubicin."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-003550","json":"https://secwatch.observer/filing/0001683168-24-003550.json","markdown":"https://secwatch.observer/filing/0001683168-24-003550.md","text":"https://secwatch.observer/filing/0001683168-24-003550.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/cns_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T21:31:25.245013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8144647eedf7a0dd41310a000a10866b0e0a21f2","claim":"CNS Pharmaceuticals, Inc. reported the first quarter 2024 ended March 31, 2024 results: net income approximately $3.5 million, EPS $(0.34) per diluted share.","evidence_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001628280-26-039379","ticker":null,"company_name":"DAVEY TREE EXPERT CO","filed_at":"2026-06-01T17:50:11+00:00","headline":"Davey Tree Q1 net loss widens to $10.7M; revenue flat at $435.8M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039379","json":"https://secwatch.observer/filing/0001628280-26-039379.json","markdown":"https://secwatch.observer/filing/0001628280-26-039379.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/davey-20260528.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"Exchange Act, unless such subsequent filing specifically references this Form 8-K. \n\n--- EX-99.1 (EX-99.1) ---\n\nTo Our Shareholders, The Company’s first quarter 2026 revenue of $435.8 million increased slightly from the record first quarter 2025 revenue by $1.0 million, or 0.2%. This growth was driven by consistent demand in the Utility segment, where revenue","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/277638/000162828026039379/0001628280-26-039379-index.htm"}},{"accession":"0000029332-26-000027","ticker":"DXYN","company_name":"DIXIE GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Dixie Group Q1 2026 net income $1.4M vs loss of $1.6M YoY; sales down 5.7%","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000029332-26-000027","json":"https://secwatch.observer/filing/0000029332-26-000027.json","markdown":"https://secwatch.observer/filing/0000029332-26-000027.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/dxyn-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"2026) -- The Dixie Group, Inc. (OTCQB: DXYN) today reported financial results for the quarter ended March 28, 2026. For the first quarter of 2026, the Company had net sales of $59,380,000 as compared to $62,990,000 in the same quarter of 2025. The Company had an operating income of $3,264,000 in the first quarter of 2026 compared to an operating income of $11,000","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/29332/000002933226000027/0000029332-26-000027-index.htm"}},{"accession":"0001043000-26-000016","ticker":"SNDA","company_name":"SONIDA SENIOR LIVING, INC.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sonida Senior Living reports Q1 net loss of $41.2M; revenue up 37% on CHP acquisition","event_type":"earnings","sec_items":["2.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001043000-26-000016","json":"https://secwatch.observer/filing/0001043000-26-000016.json","markdown":"https://secwatch.observer/filing/0001043000-26-000016.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/snda-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"Sonida Senior Living Announces First Quarter 2026 Results DALLAS, Texas – May 11, 2026 – Sonida Senior Living, Inc. (the “Company,” “Sonida,” “we,” “our,” or “us”) (NYSE: SNDA), a leading owner, operator and investor of senior housing communities, today announced its results for the first quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1043000/000104300026000016/0001043000-26-000016-index.htm"}},{"accession":"0001104659-26-058204","ticker":"EXPI","company_name":"eXp World Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"eXp World Holdings Q1 revenue $1.0B (+5% YoY), net loss narrows to $(5.1M), Adj. EBITDA $4.1M (+88%)","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058204","json":"https://secwatch.observer/filing/0001104659-26-058204.json","markdown":"https://secwatch.observer/filing/0001104659-26-058204.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/agnt-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"the company's scale and our focus on operational efficiency across eXp World Holdings,” said Jesse Hill, Chief Financial Officer of eXp World Holdings. “We generated revenue of $1.0 billion and Adjusted EBITDA of $4.1 million, an 88% improvement that further strengthened our financial position. More recently, we executed the strategic NextHome acquisition using cash","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1495932/000110465926058204/0001104659-26-058204-index.htm"}},{"accession":"0001104659-26-058287","ticker":"BATRA","company_name":"Atlanta Braves Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Atlanta Braves Holdings Q1 revenue up 53% to $72M; operating loss narrows to $41M","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-058287","json":"https://secwatch.observer/filing/0001104659-26-058287.json","markdown":"https://secwatch.observer/filing/0001104659-26-058287.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/0001104659-26-058287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/batra-20260511x8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"Total revenue grew to $72 million in the first quarter of 2026, up 53% from the prior year period.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1958140/000110465926058287/0001104659-26-058287-index.htm"}},{"accession":"0001193125-26-215645","ticker":"SBH","company_name":"Sally Beauty Holdings, Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"Sally Beauty Q2 sales up 2.3%; GAAP EPS $0.43 beats year-ago $0.38; guidance range narrowed","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215645","json":"https://secwatch.observer/filing/0001193125-26-215645.json","markdown":"https://secwatch.observer/filing/0001193125-26-215645.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368458/000119312526215645/0001193125-26-215645-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368458/000119312526215645/d76806d8k.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"Consolidated net sales of $903 million, an increase of 2.3% compared to the prior year; • Consolidated comparable sales growth of 1.3%; • Global e-commerce sales increased 13% to $108 million, representing 12% of net sales; • GAAP gross margin expansion of 70 basis points to 52.7%; • Adjusted Gross Margin expansion of 80 basis points to 52.8%; • GAAP selling, general and administrative expenses of $404 million, an increase of $14 million compared to the prior year; • Adjusted Selling, General and Administrative Expenses of $404 million, an increase of $20 million compared to the prior year; • GAAP operating earnings of $72 million and GAAP operating margin of 8.0%; • Adjusted Operating Earnings of $73 million and Adjusted Operating Margin of 8.1%; • GAAP diluted net earnings per share of $0.43, an increase of 13% compared to the prior year;","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1368458/000119312526215645/0001193125-26-215645-index.htm"}},{"accession":"0001193125-26-215661","ticker":"APC","company_name":"ARKO Petroleum Corp.","filed_at":"2026-05-11T23:59:59+00:00","headline":"ARKO Petroleum Q1 net income $8.1M ($4.5M), Adj. EBITDA $36.4M ($30.9M); completes IPO","event_type":"earnings","sec_items":["2.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215661","json":"https://secwatch.observer/filing/0001193125-26-215661.json","markdown":"https://secwatch.observer/filing/0001193125-26-215661.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2080921/000119312526215661/0001193125-26-215661-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2080921/000119312526215661/apc-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Key Highlights (vs. Year-Ago Period) 1,2 • Net income for the quarter increased to $8.1 million compared to $4.5 million. • Adjusted EBITDA for the quarter increased to $36.4 million compared to $30.9 million. • Net cash provided by operating activities for the quarter was","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2080921/000119312526215661/0001193125-26-215661-index.htm"}},{"accession":"0001193125-26-215679","ticker":"HAIN","company_name":"HAIN CELESTIAL GROUP INC","filed_at":"2026-05-11T23:59:59+00:00","headline":"Hain Celestial reports Q3 FY2026 earnings; detailed figures not included in filing excerpt","event_type":"earnings","sec_items":["2.02","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: earnings_release","same SEC item: 2.02, 9.01","same event type: earnings","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-215679","json":"https://secwatch.observer/filing/0001193125-26-215679.json","markdown":"https://secwatch.observer/filing/0001193125-26-215679.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/0001193125-26-215679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/hain-20260511.htm"},"side_by_side_evidence":{"fact_type":"earnings_release","source_excerpt":"CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1729427/000168316824003550/0001683168-24-003550-index.htm","comparable_excerpt":"On May 11, 2026, The Hain Celestial Group, Inc. (the “Company”) issued a press release announcing financial results for its third quarter ended March 31, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/910406/000119312526215679/0001193125-26-215679-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}